ICU Medical (NASDAQ:ICUI) Raised to Buy at StockNews.com

ICU Medical (NASDAQ:ICUI) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Sunday.

Several other equities research analysts also recently issued reports on ICUI. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research note on Tuesday, April 8th. KeyCorp reduced their price objective on ICU Medical from $209.00 to $191.00 and set an “overweight” rating for the company in a research note on Monday, April 21st. Finally, Raymond James reduced their price objective on ICU Medical from $197.00 to $187.00 and set a “strong-buy” rating for the company in a research note on Friday, May 9th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, ICU Medical presently has a consensus rating of “Buy” and an average price target of $192.67.

ICU Medical Trading Up 0.6%

Shares of NASDAQ ICUI opened at $141.38 on Friday. ICU Medical has a 12 month low of $100.91 and a 12 month high of $196.26. The company has a market cap of $3.48 billion, a price-to-earnings ratio of -30.94 and a beta of 0.87. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75. The business has a fifty day simple moving average of $140.85 and a 200-day simple moving average of $153.95.

ICU Medical (NASDAQ:ICUI) last announced its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 EPS for the quarter, beating the consensus estimate of $1.23 by $0.49. The business had revenue of $599.49 million during the quarter, compared to the consensus estimate of $574.15 million. ICU Medical had a positive return on equity of 5.05% and a negative net margin of 4.74%. ICU Medical’s revenue was up 6.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.96 earnings per share. Sell-side analysts predict that ICU Medical will post 4.11 EPS for the current year.

Insider Buying and Selling

In other news, Director David C. Greenberg sold 1,942 shares of the firm’s stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $143.66, for a total transaction of $278,987.72. Following the completion of the sale, the director now directly owns 6,760 shares of the company’s stock, valued at $971,141.60. This trade represents a 22.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Christian B. Voigtlander sold 5,556 shares of the firm’s stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $138.65, for a total value of $770,339.40. Following the sale, the chief operating officer now directly owns 2,389 shares of the company’s stock, valued at $331,234.85. This trade represents a 69.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 15,053 shares of company stock valued at $2,077,027. Corporate insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On ICU Medical

Hedge funds and other institutional investors have recently made changes to their positions in the company. Harvest Fund Management Co. Ltd acquired a new position in shares of ICU Medical during the 4th quarter valued at about $33,000. Quarry LP increased its holdings in shares of ICU Medical by 764.3% during the 4th quarter. Quarry LP now owns 242 shares of the medical instruments supplier’s stock valued at $38,000 after acquiring an additional 214 shares during the last quarter. Murphy & Mullick Capital Management Corp acquired a new position in shares of ICU Medical during the 4th quarter valued at about $52,000. Venturi Wealth Management LLC increased its holdings in shares of ICU Medical by 64.0% during the 4th quarter. Venturi Wealth Management LLC now owns 528 shares of the medical instruments supplier’s stock valued at $82,000 after acquiring an additional 206 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in shares of ICU Medical by 88.8% during the 4th quarter. Russell Investments Group Ltd. now owns 638 shares of the medical instruments supplier’s stock valued at $99,000 after acquiring an additional 300 shares during the last quarter. 96.10% of the stock is owned by hedge funds and other institutional investors.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.